RT Journal Article
SR Electronic
T1 Genetic risk factor clustering within and across neurodegenerative diseases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.01.22282945
DO 10.1101/2022.12.01.22282945
A1 Mathew J. Koretsky
A1 Chelsea Alvarado
A1 Mary B Makarious
A1 Dan Vitale
A1 Kristin Levine
A1 Anant Dadu
A1 Sonja W. Scholz
A1 Lana Sargent
A1 Faraz Faghri
A1 Hirotaka Iwaki
A1 Cornelis Blauwendraat
A1 Andrew Singleton
A1 Mike Nalls
A1 Hampton Leonard
YR 2022
UL http://medrxiv.org/content/early/2022/12/03/2022.12.01.22282945.abstract
AB Overlapping symptoms and copathologies are common in closely related neurodegenerative diseases (NDDs). Investigating genetic risk variants across these NDDs can give further insight into disease manifestations. In this study we have leveraged genome-wide single nucleotide polymorphisms (SNPs) and genome-wide association study (GWAS) summary statistics to cluster patients based on their genetic status across identified risk variants for five NDDs (Alzheimer’s disease [AD], Parkinson’s disease [PD], amyotrophic lateral sclerosis [ALS], Lewy body dementia [LBD], and frontotemporal dementia [FTD]). The multi-disease and disease-specific clustering results presented here provide evidence that NDDs have more overlapping genetic etiology than previously expected and how neurodegeneration should be viewed as a spectrum of symptomology. These clustering analyses also show potential subsets of patients with these diseases that are significantly depleted for any known common genetic risk factors suggesting environmental or other factors at work. Establishing that NDDs with overlapping pathologies share genetic risk loci, future research into how these variants might have different effects on downstream protein expression, pathology and NDD manifestation in general is important for refining and treating NDDs.Competing Interest StatementC.A., K.L., H.L., H.I., D.V., F.F. and M.N.'s participation in this project was part of a competitive contract awarded to Data Tecnica International LLC by the National Institutes of Health to support open science research. M.N. also currently serves on the scientific advisory board for Clover Therapeutics and is an advisor to Neuron23 Inc.Funding StatementNo funding was received towards this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data used in the preparation of this article were obtained from the AMP-PD Knowledge Platform. For up-to-date information on the study, visit https://www.amp-pd.org. The results published here are in whole or in part based on data obtained from the AD Knowledge Portal (https://adknowledgeportal.org).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll samples for this analysis were obtained from public domain WGS cohorts. A repository containing all code for processing and analysis is publicly available to facilitate replication (https://github.com/NIH-CARD/NDD_risk_variant_clustering). In addition, an interactive website has been developed where researchers can further explore the described cluster memberships and results (https://nih-card-ndd-risk-variant-clustering-app-25rr5g.streamlitapp.com/).ADAlzheimer’s diseaseADNIAlzheimer’s disease Neuroimaging InitiativeADSPAlzheimer’s Disease Sequencing ProjectALSAmyotrophic lateral sclerosisAMP-PDAccelerating Medicines Partnership Parkinson’s diseaseAUCArea under the receiving operating characteristic curveFTDFrontotemporal dementiaGP2Global Parkinson’s Genetics ProgramGRMGenetic relatedness matrixGWASGenome-wide association studyLBDLewy body dementiaLDLinkage disequilibriumMAFMinor allele frequencyMayoRNAseqMayo RNAseq StudyNDDNeurodegenerative diseaseOROdds ratioPCAPrincipal component analysisPDParkinson’s diseasePRSPolygenic risk scoreQCQuality controlROCReceiving operating characteristicROSMAPReligious Orders Study/Memory and Aging ProjectSEStandard errorSNPSingle nucleotide polymorphismUMAPUnified Manifold Approximation and ProjectionWGSWhole genome sequencing